Circumventing the effect of product toxicity: Development of a novel two-stage production process for the lantibiotic gallidermin

Applied and Environmental Microbiology

Volumn 73, Issue 5, 2007, Pages 1635-1645

  Valsesia, G ^a   Medaglia, G ^a   Held, M ^a   Minas, W ^b   Panke, S ^a  

^a ETH ZURICH   (Switzerland)

^b Biotech Concepts GmbH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FOOD AREA; GALLIDERMIN PRODUCTION; LANTIBIOTIC GALLIDERMIN; SPECIFIC ACTIVITY;

BACTERIA; BIOASSAY; DISEASES; GENE TRANSFER; MASS SPECTROMETRY; POLYPEPTIDES; TOXICITY;

ANTIBIOTICS;

GALLIDERMIN; LANTIBIOTIC; PREGALLIDERMIN PROTEASE; PROTEINASE; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ANTIBIOTICS; BACTERIUM; MUTATION; PEPTIDE; TOXICITY TEST;

AMINO ACID SEQUENCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BIOASSAY; DRUG SYNTHESIS; DRUG TOXICITY; EVALUATION; FERMENTATION; FILTER; GDMA GENE; GENE CONSTRUCT; GENE SEQUENCE; KANAMYCIN RESISTANCE GENE; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; SEQUENCE ANALYSIS; STAPHYLOCOCCUS; STAPHYLOCOCCUS GALLINARIUM;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIOCINS; BIOTECHNOLOGY; GENE EXPRESSION REGULATION, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MULTIGENE FAMILY; MUTATION; PEPTIDE HYDROLASES; PEPTIDES; PROTEIN PRECURSORS; SEQUENCE ANALYSIS, DNA; STAPHYLOCOCCUS;

POSIBACTERIA; STAPHYLOCOCCUS GALLINARUM;

EID: 33947230536     PISSN: 00992240     EISSN: None     Source Type: Journal    
DOI: 10.1128/AEM.01969-06     Document Type: Article

References (62)

1. Allgaier, H., G. Jung, R. G. Werner, U. Schneider, and H. Zähner. 1985. Elucidation of the structure of epidermin, a ribosomally synthesized, tetracyclic heterodetic polypeptide antibiotic. Angew. Chem. Int. Ed. 24:1051-1053.
2. Augustin, J., R. Rosenstein, B. Wieland, U. Schneider, N. Schnell, G. Engelke, K. D. Entian, and E. Götz. 1992. Genetic analysis of epidermin biosynthetic genes and epidermin-negative mutants of Staphylococcus epidermidis. Eur. J. Biochem. 204:1149-1154.
3. Bhugaloo-Vial, P., W. Grajek, X. Dousset, and P. Boyaval. 1997. Continuous bacteriocin production with high cell density bioreactors. Enzyme Microb. Technol. 21:450-457.
4. Bierbaum, G., F. Götz, A. Peschel, T. Kupke, M. van der Kamp, and H. G. Sahl. 1996. The biosynthesis of the lantibiotics epidermin, gallidermin, Pep5 and epilancin K7. Antonie Leeuwenhoek 69:119-127.
5. Bonelli, R. R., T. Schneider, H. G. Sahl, and I. Wiedemann. 2006. Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies. Antimicrob. Agents Chemother. 50:1449-1457.
6. Brotz, H., M. Josten, I. Wiedemann, U. Schneider, F. Götz, G. Bierbaum, and H. G. Sahl. 1998. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol. Microbiol. 30:317-327.
7. Brückner, R. 1997. Gene replacement in Staphylococcus carnosus and Staphylococcus xylosus. FEMS Microbiol. Lett. 151:1-8.
8. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, and S. K. Fridkin. 2003. Brief report: infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.
9. Cockayne, A., P. J. Hill, N. B. Powell, K. Bishop, C. Sims, and P. Williams. 1998. Molecular cloning of a 32-kilodalton lipoprotein component of a novel iron-regulated Staphylococcus epidermidis ABC transporter. Infect. Immun. 66:3767-3774.
10. Dannesen, P. J. W., M. J. M. Bonten, and R. A. Weinstein. 1998. Multiresistant bacteria as a hospital epidemic problem. Ann. Med. 30:176-185.
11. Devos, W. M., O, P. Kuipers, J. R. van der Meer, and R. J. Siezen. 1995. Maturation pathway of nisin and other lantibiotics: posttranslationally modified antimicrobial peptides exported by gram-positive bacteria. Mol. Microbiol. 17:427-437.
12. Fiedler, H. P., T. Hörner, and H. Decker. 1988. Purification of the hydrophilic antibiotics epidermin, gallidermin and nikkomycin Z by preparative reversed-phase HPLC. Chromatographia 26:215-220.
13. Goldstein, B. P. December 1998. A method using nisin or other lanthocin for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon. U.S. patent WO9,856,398.
14. Guerout-Fleury, A. M., K. Shazand, N. Frandsen, and P. Stragier. 1995. Antibiotic-resistance cassettes for Bacillus subtilis. Gene 167:335-336.
15. Herrero, M. V., V. de Lorenzo, and K. N. Timmis. 1990. Transposon vectors containing nonantibiotic selection markers for cloning and stable chromosomal insertion of foreign DNA in gram-negative bacteria. J. Bacteriol. 172:6557-6567.
16. Hille, M. 2002. Untersuchungen zur Biosynthese der Lantibiotika Gallidermin and Epidermin. Ph.D. thesis. Eberhard-Karls-Universität, Tübingen, Germany.
17. Hille, M., S. Kies, F. Götz, and A. Peschel. 2001. Dual role of GdmH in producer immunity and secretion of the staphylococcal lantibiotics gallidermin and epidermin. Appl. Environ. Microbiol. 67:1380-1383.
18. Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59.
19. Hoffmann, A., U. Pag, I. Wiedemann, and H. G. Sahl. 2002. Combination of antibiotic mechanisms in lantibiotics. Farmaco 57:685-691.
20. Hörner, T., V. Ungermann, H. Zähner, H. P. Fiedler, R. Utz, R. Kellner, and G. Jung. 1990. Comparative studies on the fermentative production of lantibiotics by staphylococci. Appl. Microhiol. Biotechnol. 32:511-517.
21. Hörner, T., H. Zähner, R. Kellner, und G. Jung. 1989. Fermentation and isolation of epidermin, a lanthionine containing polypeptide antibiotic from Staphylococcus epidermidis. Appl. Microbiol. Biotechnol. 30:219-225.
22. Horton, R. M., Z. L. Cai, S. N. Ho, and L. R. Pease. 1990. Gene-splicing by overlap extension: tailor-made genes using the polymerase chain reaction. BioTechniques 8:528-536.
23. Horton, R. M., H. D. Hunt, S. N. Ho, J. K. Pullen, and L. R. Pease. 1989. Engineering hybrid genes without the use of restriction enzymes: gene-splicing by overlap extension. Gene 77:61-68.
24. Jack, R., F. Götz, and G. Jung. 1997. Lantibiotics, p. 323-368. In H. Kleinkauf and H. von Dören (ed.), Products of secondary metabolism, 2nd ed., vol. 7. Wiley-VCH, Weinheim, Germany.
25. Kellner, R., G. Jung, T. Hörner, H. Zähner, N. Schnell, K. D. Entian, and F. Götz. 1988. Gallidermin: a new lanthionine-containing polypeptide antibiotic. Eur. J. Biochem. 177:53-59.
26. Kempf, M., U. Theobald, and H. P. Fiedler. 1999. Correlation between the consumption of amino acids and the production of the antibiotic gallidermin by Staphylococcus gallinarum. Biotechnol. Lett. 21:959-963.
27. Kempf, M., U. Theobald, and H. P. Fiedler. 1999. Economic improvement of the fermentative production of gallidermin by Staphylococcus gallinarum. Biotechnol. Lett. 21:663-667.
28. Kies, S. 2001. Regulation von Virulenzfaktoren und der Biosynthese des Lantibiotikums Epidermin in Staphylococcus epidermidis. Ph.D. thesis. Eberhard-Karls-Universität, Tübingen, Germany.
29. Kies, S., C. Vuong, M. Hille, A. Peschel, C. Meyer, F. Götz, and M. Otto. 2003. Control of antimicrobial peptide synthesis by the agr quorum sensing system in Staphylococcus epidermidis: activity of the lantibiotic epidermin is regulated at the level of precursor peptide processing. Peptides 24:329-338.
30. Kovacs, G., J. Burghardt, S. Pradella, P. Schumann, E. Stackebrandt, and K. Marialgeti. 1999. Kocuria palustris sp. nov. and Kocuria rhizophila sp. nov., isolated from rhizoplane of the narrow-leaved cattail (Typha angustifolia). Int. J. Syst. Bacteriol. 49:167-173.
31. Kovarik, A., K. Hlubinova, A. Vrehenska, and J. Prachar. 1986. An improved colloidal silver staining method of protein blots on nitrocellulose membranes. Folia Biol. 33:253-257.
32. Kreiswirth, B. N., S. Löfdahl, M. J. Betley, M. O'Reilly, P. M. Schlievert, M. S. Bergdoll, and R. P. Novick. 1983. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 305:709-712.
33. Kruszewska, D., H. G. Suhl, G. Bierbaum, U. Pag, S. O. Hynes, and A. Ljungh. 2004. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. Antimicrob. Chemother. 54:648-653.
34. Kuipers, O. P., G. Bierbaum, B. Ottenwalder, H. M. Dodd, N. Horn, J. Metzger, T. Kupke, V. Gnau, R. Bongers, P. van den Bogaard, H. Kosters, H. S. Rollema, W. M. de Vos, R. J. Siezen, G. Jung, F. Götz, H. G. Sahl, and M. J. Gasson. 1996. Protein engineering of lantibiotics. Antonie Leeuwenhoek 69:161-169.
35. Leeb, M. 2004. A shot in the arm. Nature 431:892-893.
36. Madsen, S. M., H. C. Beck, P. Ravn, A. Vrang, A. M. Hansen, and H. Israelsen. 2002. Cloning and inactivation of a branched-chain amino acid aminotransferase gene from Staphylococcus carnosus and characterization of the enzyme. Appl. Environ. Microbiol. 68:4007-4014.
37. Nathan, C. 2004. Antibiotics at the crossroads. Nature 431:899-902.
38. Ottenwalder, B., T. Kupke, S. Brecht, V. Gnau, J. Metzger, G. Jung, and F. Götz. 1995. Isolation and characterization of genetically engineered gallidermin and epidermin analogs. Appl. Environ. Microbiol. 61:3894-3903.
39. Otto, M., A. Peschel, and F. Götz. 1998. Producer self-protection against the lantibiotic epidermin by the ABC transporter EpiFEG of Staphylococcus epidermidis Tu3298. FEMS Microbiol. Lett. 166:203-211.
40. Peel, J. E., and B. Suri. January 1998. Use of gallidermin and epidermin for preventing or treating mastitis and for reducing withholding time of milk. U.S. patent 5,710,124-A.
41. Peschel, A. 1995. Biosynthese des Lantibiotikums Epidermin: Untersuchungen zur Regulation, Immunität und Sekretion. Ph.D. thesis. Eberhard-Karls-Universität, Tübingen, Germany.
42. Peschel, A., J. Augustin, T. Kupke, S. Stevanovic, and F. Götz. 1093. Regulation of epidermin biosynthetic genes by EpiQ. Mol. Microbiol. 9:31-39.
43. Peschel, A., and F. Götz. 1996. Analysis of the Staphylococcus epidermidis genes epiF, -E, and -G involved in epidermin immunity. J. Bacteriol. 178: 531-536.
44. Peschel, A., N. Schnell, M. Hille, K. D. Entian, and F. Götz. 1997. Secretion of the lantibiotics epidermin and gallidermin: sequence analysis of the genes gdmT and gdmH, their influence on epidermin production and their regulation by EpiQ. Mol. Gen. Genet. 254:312-318.
45. Sahl, H. G., and G. Bierbaum. 1998. Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from gram-positive bacteria. Annu. Rev. Microbiol. 52:41-79.
46. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
47. Saris, P. E. J., T. Immonen, M. Reis, and H. S. Sahl. 1996. Immunity to lantibiotics. Antonic Leeuwenhoek 69:151-159.
48. Schägger, H., and G. von Jagow. 1987. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166:368-379.
49. Schenk, S., and R. A. Laddaga. 1992. Improved method for electroporation of Staphylococcus aureus. FEMS Microbiol. Lett. 94:133-138.
50. Schnell, N., G. Engelke, J. Augustin, R. Rosenstein, V. Ungermann, F. Götz, and K. D. Entian. 1992. Analysis of genes involved in the biosynthesis of the lantibiotic epidermin. Eur. J. Biochem. 204:57-68.
51. Schnell, N., K. D. Entian, F. Götz, T. Horner, R. Kellner, and G. Jung. 1989. Structural gene isolation and prepeptide sequence of gallidermin, a new lanthionine containing antibiotic. FEMS Microbiol. Lett. 58:263-267.
52. Schnell, N., K. D. Entian, U. Schneider, F. Götz, H. Zähner, R. Kellner, and G. Jung. 1988. Prepeptide sequence of epidermin, a ribosomally synthesized antibiotic with 4 sulfide-rings. Nature 333:276-278.
53. Shams-Eldin, H., F. Debierre-Grockiego, and R. T. Schwarz. 2003. Chased PCR: a modified inverse PCR technique to characterize flanking regions of AT-rich DNA fragments. J. Mol. Microbiol. Biotechnol. 6:1-5.
54. Taniguchi, M., K. Hoshino, H. Urasaki, and M. Fujii. 1994. Continuous production of an antibiotic polypeptide (nisin) by Lactococcus lactis using a bioreactor coupled to a microfiltration module. J. Ferment. Bioeng. 77:704-708.
55. Theobald, U. 2001. Fermentation of lantibiotics epidermin and gallidemin, p. 93-101. In V. Braun and F. Götz (ed.), Microbial fundamentals of biotechnology. Wiley-VCH, Bonn, Germany.
56. Theobald, U., and M. Kempf. 1998. A novel tool for medium optimization and characterization in the early stages of a metabolite production process. Biotechnol. Tech. 12:893-897.
57. Ungermann, V. 1992. Untersuchungen zur Produktbildung und Scale-Up der Produktion von Gallidermin einem lanthioninhaltigen Peptidanlibiotikum aus Staphylococcus gallinarum Tü3928. Ph.D. thesis. Eberhard-Karls- Universität, Tübingen, Germany.
58. Ungermann, V., K. Goeke, H.-P. Fiedler, and H. Zähner. 1991. Optimization of fermentation and purification of gallidermin and epidermin, p. 410-420. In G. Jung and H.-G. Sahl (ed.), Nisin and novel lantibiotics. ESCOM Science Publishers, Leiden, The Netherlands.
59. van der Meer, J. R., J. Polman, M. M. Beerthuyzen, R. J. Siezen, O. P. Kuipers, and W. M. Devos. 1993. Characterization of the Lactococcus lactis nisin A operon genes nisP, encoding a subtilisin-like serine protease involved in precursor processing, and nisR, encoding a regulatory protein involved in nisin biosynthesis. J. Bacteriol. 175:2578-2588.
60. van Heusden, H. E., B. de Kruijff, and E. Breukink. 2002. Lipid II induces a transmembrane orientation of the pore-forming peptide lantibiotic nisin. Biochemistry 41:12171-12178.
61. Wiedemann, I., E. Breukink, C. van Kraij, O. P. Kuipers, G. Bierbaum, B. de Kruijff, and H. G. Sahl. 2001. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J. Biol. Chem. 276:1772-1779.
62. Zäbner, H., F. Götz, T. Hörner, R. G. Werner, H. Allgaier, G. Jung, and R. Kellner. 1998. New peptide antibiotic gallidermin is produced by Staphylococcus gallinarum and used esp. for treating eczema, impetigo, cellulitis and acne. U.S. patent 5,843,709-A.